Enosi Life Sciences Launches Regulation D Offering to Fund Antibody Therapeutics Development

Capital raised from the Regulation D offering will support the continued development of Enosi’s novel “second generation” anti-TNF therapeutics

SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) — Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for autoimmune disease, cancer, and acute inflammation, today announced the launch of its Regulation D offering, following the filing of its Form D by the U.S. Securities and Exchange Commission. Details of the offering can be found here.

The purpose of this offering is to grant accredited investors the opportunity to invest in next generation therapeutics for autoimmune disease and cancer. Enosi’s approach combines technologies from cancer and autoimmune disease research to create more effective and targeted therapeutics that can circumvent current therapeutic shortfalls with precision focus. Enosi’s Regulation D 506(c) private offering allows the company to sell up to $8,000,000 worth of shares to accredited investors.

Enosi fills a substantial gap that currently exists in the TNF inhibitor market, which is valued at over $40 billion per annum. Existing TNF inhibitors block both TNF receptors (TNFR 1 and TNFR2) and have black box warnings related to opportunistic infections, cancer and cardiovascular events. Enosi’s therapeutics precisely target the inflammatory TNFR1 and subsequently do not block the anti-inflammatory TNFR2, which Enosi expects will yield improved patient outcomes. Furthermore, these solutions offer the potential to treat the inflammation that occurs in most solid tumors, thereby complementing the global cancer immunotherapy market which is expected to reach $115 billion by 2026.

“We are excited to officially launch our Regulation D offering, creating an opportunity for a broader base of shareholders to invest in a company with proven experience in drug research and development, established contacts across top-tier networks, and internationally-recognized leadership with a successful track record in cutting edge antibody therapeutic development,” said Dr. H. Michael Shepard, President, CSO and CEO of Enosi Life Sciences. “Our team has played a role in many of the leading therapeutics currently available on the market today for cancer, inflammation and autoimmune disease. We’ve long understood the benefits and deficiencies of existing therapeutics and we believe that our approach will once again open the door for more effective treatments.”

“Everyone today personally knows patients with cancer, autoimmune disease or other inflammatory conditions, whether it’s a relative or friend who has or is currently suffering from these diseases. Our Regulation D private offering is the first of a series of opportunities to enable the broader public to invest in what we are confident will be improved and vastly expanded solutions for patients with these diseases,” said Sir Marc Feldmann, Co-Founder and Board Member of Enosi Life Sciences. “Dr. H. Michael Shepard, our newly recruited Executive Chairman, Dr. James N. Woody, and I have led the development of the first monoclonal antibody treatments that revolutionized the treatment of inflammatory diseases such as rheumatoid arthritis, and of cancer. We believe that by teaming up, we can again deliver breakthrough products for patients with major unmet needs.”

Capital raised through the Regulation D 506(c) offering will support Enosi’s efforts to progress the Company’s molecules that target autoimmune disease, cancer and acute inflammation toward clinical trials. Initial product candidates include EN1001; an anti-TNFR1 therapeutic and EN2001; a growth factor trap for Rheumatoid Arthritis.

About Enosi Life Sciences Corp.
Enosi Life Sciences Corp. is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker award, 2003); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins (Lasker award, 2019). Enosi Life Sciences combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Life Sciences, visit www.enosi-life.com.

IR Contact
Tom Becker
investment@enositherapeutics.com

Media Relations Contact
Kate Caruso-Sharpe
FischTank PR
enosi@fischtankpr.com
646-699-1534

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.